UCB stock: Guidance raised again on strong drug demand

Published on 11/02/2026 at 10:54 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

UCB stock follows another upgrade to the company's 2026 outlook. Stronger BIMZELX demand and continued CIMZIA growth support the revised targets.

UCB raises its 2026 outlook

UCB lifted its 2026 revenue and adjusted EBITDA growth expectations again on October 22.
BIMZELX demand in the United States and continued CIMZIA volume growth are driving the upgrade.
Full-year 2026 results and formal 2027 guidance are scheduled for February 25, 2027.

UCB, BE0003739530, Illustration mit AI erstellt.

UCB raised its 2026 financial guidance again on Thursday, October 22, citing stronger demand for BIMZELX and continued volume growth for CIMZIA. The Brussels-based biopharmaceutical company said revenue growth should reach the low twenties at constant exchange rates, compared with the previous low- to mid-teens range.

UCB stock traded at 280.10 euros on Lang & Schwarz at 10:47:43 CET on Monday, November 2, 2026. The quote reflects the company's Belgian listing and is not presented here with a daily percentage comparison because the relevant Xetra closing basis could not be established.

Higher growth, stronger operating leverage

The October 22 announcement also lifted the outlook for adjusted EBITDA growth to the low- to mid-forties at constant exchange rates. The previous expectation ranged from the mid-teens to the low twenties. UCB said faster revenue growth should create significant operating leverage and margin expansion.

The upgrade is based primarily on BIMZELX, the company's bimekizumab treatment. UCB said volume growth continued across indications, with faster patient conversion and higher retention rates. The company attributed the momentum to focused investment, broader access, the medicine's clinical profile and BE BOLD study data. A more favorable channel mix also improved net pricing and value per patient.

CIMZIA continued to contribute despite a contracting anti-TNF market, according to UCB. The company cited volume growth across markets, more favorable pricing, optimized claims diligence and the impact of a recent Orphan Drug Designation. CFO Sandrine Dufour said the performance of BIMZELX and CIMZIA showed that UCB could translate innovation into revenue growth, operating leverage and profitability while continuing to invest in its pipeline. These statements and the revised targets come from UCB's October 22 press release.

What investors should watch next

The revised guidance excludes proceeds from the planned sale of a Priority Review Voucher. UCB said that transaction could add a further low- to mid-single-digit percentage-point uplift to revenue and adjusted EBITDA, respectively. The company generated revenue of 7.7 billion euros in 2025.

UCB will publish its full-year 2026 results and formal financial guidance for 2027 on February 25, 2027. The next report will show whether the stronger U.S. demand for BIMZELX and the contribution from CIMZIA translated into the expected earnings leverage.

Investors can follow the real-time quote of UCB stock during the session.

The Euro Stoxx 50 provides the broader eurozone market context without implying index membership for UCB.

More news and analyses on UCB stock.